CD274 and non-small cell lung carcinoma: Similarly, atezolizumab, administered as monotherapy to NSCLC patients with high PD‐L1 expression in tumor or immune cells, or in combination with platinum‐based chemotherapy to all NSCLC patients regardless of PD‐L1 expression status, was more effective than the platinum‐based chemotherapy.